Skip to content. | Skip to navigation

Personal tools

Navigation path

Alternative Testing Strategies Progress report 2009. Replacing, Reducing And Refining Use Of Animals In Research.

News details
Jul 01, 2009
EC, Directorate-General for Research - Directorate F — Health - Unit F.5 — Health Biotechnology

Genomics & Biotechnology. Eur 23886 - Luxembourg: OPOCE, 2009 ISBN 978-92-79-11949-1 doi 10.2777/21412 ISSN 1018-5593 © European Communities, 2009

This document (issued by the EC Directorate-General for Research in 2009) is made available on the IHCP web site for reference purposes.


ReProTect assembled 33 different European partners from Academia, Industry including small to medium-sized enterprises (SMEs) and Governmental Institutes.
The overall aim of ReProTect was to develop new in vitro models and to improve existing ones, in order to include them into a testing strategy aimed at providing detailed information on the hazard of compounds to the mammalian reproductive cycle.

More on this Report on the CORDIS Library website.

Download it from the CORDIS websitepdf icon.


Its Table of contents is reproduced below.



1.1 Human safety, products safety

1.2 The 3Rs Principle and the legislative framework

1.3 Often-expressed concerns about the replacement of animals in scientific experiments

1.4 Institutions and organisations in the field of safety assessment and alternative testing methods

2. Projects supported by the EU Health programme


2.1 Cell-based technologies

  • ReProTect Development of a novel approach in hazard and risk assessment of reproductive toxicity by a combination and application of in vitro, tissue and sensor technologies

  • VITROCELLOMICS Reducing animal experimentation in preclinical predictive drug testing by human hepatic in vitro models derived from embryonic stem cells

  • MEMTRANS Membrane transporters: in vivo models for the study of their role in drug fate

  • EXERA Development of 3D in vitro models of estrogenreporter mouse tissues for the pharmaco-toxicological analysis of nuclear receptors-interacting compounds (NR-ICs)

  • INVITROHEART Reducing animal experimentation in drug testing by human cardiomyocyte in vitro models derived from embryonic stem cells

  • LIINTOP Optimisation of liver and intestine in vitro models for pharmacokinetics and pharmacodynamics studies

  • ARTEMIS In vitro neural tissue system for replacement of transgenic animals with memory/learning deficiencies

  • ESNATS Embryonic stem cell-based novel alternative testing Strategies


2.2 Integrated testing strategies

  • ACuteTox Optimisation and pre-validation of an in vitro test strategy for predicting human acute toxicity


2.3 -omics, bioinformatics and computational biology

  • Predictomics Short-term in vitro assays for long-term toxicity

  • Sens-it-iv Novel testing strategies for in vitro assessment of allergens

  • carcinoGENOMICS Development of a high throughput genomics-based test for assessing genotoxic and carcinogenic properties of chemical compounds in vitro

  • PREDICT-IV Profiling the toxicity of new drugs: a non-animal based approach integrating toxicodynamics and biokinetics


2.4 Computational modelling and estimation techniques

  • OpenTox Promotion, development, acceptance and implementation of QSARs (quantitative structure-activity relationships) for toxicology

2.5 High throughput techniques

  • TOXDROP Innovative ‘Cell-on-Chip’ technology to screen chemicals for toxicity, using cultured cells within tiny ‘nanodrops’ of culture fluid

  • COMICS Comet assay and cell array for fast and efficient genotoxicity testing

  • NanoTEST Development of methodology for alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics


2.6 Forums and Workshops

  • CONAM Consensus networking on alternatives within Europe

  • SCARLET Structure-activity relationships: experts’ workshop in mutagenicity and carcinogenicity

  • ForInViTox Forum for researchers and regulators to meet manufacturers of toxicology test methods

  • InViToPharma Workshop on the need for in vitro toxicity tests within the pharmaceutical industry

3. Future steps


3.1 Defining the state of the art in 3Rs

  • START-UP Scientific and technological issues in 3Rs alternatives research in the process of drug development and Union politics

3.2 Transition to a toxicity pathway-based paradigm

  • AXLR8 Accelerating the transition to a toxicity pathwaybased paradigm for chemical safety assessment through internationally co-ordinated research and technology development

3.3 A possible strategy for the replacement of animals in repeated dose systemic toxicity testing

4. Alphabetical index of projects

5. Index of coordinators